Use of this company’s Actifuse bone graft material in operations such as spinal fusion and trauma repair has doubled in the past year. Apatech says 2,000 surgeons use it worldwide in 1,000 hospitals. Driven by research done at the University of London and Cambridge, the success of the company’s synthetic bone graft products has secured £23m in private equity from 3i and the New York hedge fund Healthcor. Led by chief executive Simon Cartmell, the company has increased its sales 205% a year from £270,000 in 2005 to £7.6m in 2008.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.